Lannett enters advisory services agreement with Cediprof
Lannett has entered into a three-year advisory services agreement with its strategic alliance partner, Cediprof, a subsidiary of Neolpharma Group.
The agreement is separate and in addition to the supply and distribution agreement for levothyroxine sodium tablets recently entered into by the companies.
Under the new agreement, Lannett will advise on a wide array of matters broadly related to assisting Cediprof and its affiliated entities with their efforts to further develop and commercialize products for the U.S. generic market. Lannett will receive an advisory fee for its services.
"We have formed a strong working relationship with Cediprof and look forward to providing our expertise and assistance to help Cediprof establish, in due course, an expanded presence in the United States generic drug market," Lannett CEO Tim Crew said. "We bring a deep knowledge of the U.S. generic drug market, which Cediprof can leverage across its broad portfolio and operational footprint. Our mutual desire is to further expand the relationship and, we eventually expect to commercialize for the U.S. market certain products in the oncolytic and hormonal therapeutic categories, including injectables, that are currently within Cediprof's development and manufacturing capabilities."
The agreement is separate and in addition to the supply and distribution agreement for levothyroxine sodium tablets recently entered into by the companies.
Under the new agreement, Lannett will advise on a wide array of matters broadly related to assisting Cediprof and its affiliated entities with their efforts to further develop and commercialize products for the U.S. generic market. Lannett will receive an advisory fee for its services.
"We have formed a strong working relationship with Cediprof and look forward to providing our expertise and assistance to help Cediprof establish, in due course, an expanded presence in the United States generic drug market," Lannett CEO Tim Crew said. "We bring a deep knowledge of the U.S. generic drug market, which Cediprof can leverage across its broad portfolio and operational footprint. Our mutual desire is to further expand the relationship and, we eventually expect to commercialize for the U.S. market certain products in the oncolytic and hormonal therapeutic categories, including injectables, that are currently within Cediprof's development and manufacturing capabilities."